Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Uniphar increases profit in H1 2026 and confirms EBITDA target for 2028
Uniphar reports adjusted EPS of EUR 0.109 in H1 2026 (+11.2%), gross profit of EUR 236.5m (+7.7%) and EBITDA of EUR 61.1m (+6.2%). Return on capital employed (ROCE) was 14.7%, and free cash flow was negative at EUR -47m, which is attributed to timing effects in working capital. Management reaffirmed the mid‑term target of EUR 200m EBITDA by 2028 and expects double‑digit growth in Pharma and continued growth in Medtech; the commissioning of the new Greenogue 2 distribution centre has been delayed to February 2027. » Mere på de.investing.com
Uniphar executives trade shares from remuneration plan
Senior executives of Uniphar carried out share purchases and sales under the company’s share-based remuneration plan through the Uniphar plc Employee Benefit Trust. CEO Gerard Rabbette bought 111,088 ordinary shares and sold 233,068 ordinary shares; CFO Timothy Dolphin bought 74,059 and sold 155,378 ordinary shares — all transactions at €3.8629 per share. After the transactions Rabbette holds 7,334,772 and Dolphin holds 5,610,856 ordinary shares. The dealings were reported on Euronext Dublin via Intertrust Trustee (Ireland) Limited as trustee and are based on a disclosure under Article 19 of the Market Abuse Regulation. » Mere på de.investing.com
Uniphar schedules general meeting for 7 May and sends annual report
Uniphar has scheduled its annual general meeting for 7 May 2026 at 11:00 in the premises of William Fry LLP in Dublin and has sent the annual report for the year ended 31 December 2025 to shareholders. Shareholders may attend in person, vote by proxy, or follow the meeting by telephone as listeners only; questions must be submitted in writing with the shareholder reference number by 5 May 2026 at 17:00. The notice, proxy form and annual report are available on the company website and for inspection at the registered office during normal business hours. » Mere på de.investing.com
Uniphar reports 9% organic gross profit growth and beats 2025 earnings expectations
Uniphar recorded 9% organic gross profit growth in 2025 and adjusted earnings per share that rose by around 21%, outperforming the 14% consensus forecast. Drivers included lower financing costs and effects from a €35m share buyback programme. Net debt at year-end stood at 1.5x EBITDA, roughly €90m below analyst expectations, supported by positive working capital. Uniphar confirms its target to reach €200m EBITDA by 2028 (including €20m from M&A) and sets 2026 growth targets for its divisions: Pharma (double-digit), Medtech (high single-digit) and Supply Chain & Retail (low single-digit); the new logistics centre and ERP remain on schedule for the summer. » Mere på de.investing.com
Santhera agrees exclusive distribution deal for AGAMREE with Uniphar for five GCC states
Santhera Pharmaceuticals has signed an exclusive distribution partnership with Uniphar for AGAMREE (Vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain; sales via a named-patient program are due to start in Q1 2026, with broader commercial distribution expected after approval at the end of 2026. Santhera will receive sales-based compensation and stresses that the agreement is intended to accelerate access to the therapy for DMD patients in the region. The drug is already approved in several regions and Santhera names additional licensing partners for certain markets. » Mere på finanzen.net
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 1,57 mia. | - |
| Bruttofortjeneste | 216,56 mio. | - |
| Nettoresultat | 19,73 mio. | - |
| EBITDA | 57,87 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,13 mia. € |
Antal aktier | 259,57 mio. |
Højeste/laveste i 52 uger | 5,14 € - 3,53 € |
Udbytteafkast | 0,47 % |
Udbytte TTM | 0,0205 € |
Beta | 1,16 |
P/E (PE Ratio) | 21,01 |
PEG (PEG Ratio) | -1,31 |
K/I (PB Ratio) | 2,62 |
P/S (PS Ratio) | 0,36 |
Virksomhedsprofil
Uniphar plc driver en diversificeret sundhedsservicevirksomhed i Republikken Irland, Storbritannien og internationalt. Virksomheden er organiseret i tre divisioner: Commercial & Clinical, Product Access og Supply Chain & Retail. Divisionen Commercial & Clinical tilbyder outsourcet salg, markedsføring og multikanal kundeansvarlighed (multichannel account management) til producenter af farmaceutiske og medicinske produkter; samt distribution og supportydelser til producenter af medicinsk udstyr. Divisionen Product Access leverer on demand-tjenester, som giver adgang til farmaceutiske produkter og behandlinger ved at udvikle værdifulde relationer og interaktioner mellem producenter og andre aktører i sundhedssektoren; og exclusive access-tjenester, der tilbyder skræddersyede distributionspartnerskaber til farmaceutiske partnere for nøglemærker. Divisionen Supply Chain & Retail beskæftiger sig med pre-grossist- og grossistdistribution af farmaceutiske produkter, sundhedsprodukter og dyresundhedsprodukter til apoteker, hospitaler og dyrlæger; og driver et netværk af apoteker under mærkerne Life, Allcare og Hickey's. Divisionen tilbyder også apoteksstøtte, farmaceutisk forsyningskæde, specialiseret sygepleje og infusionsbehandling, distribution af medicinsk udstyr, sundhedsteknologi, dataintelligens og konsulentydelser, farmaceutisk rådgivning, medicinske anliggender samt online-apotek og produktfostringstjenester, samt dataløsninger til farmaceutisk industri. Uniphar plc blev grundlagt i 1967 og har hovedkvarter i Dublin, Irland.
| Navn | UNIPHAR PLC EO -,08 |
| CEO | Gerard Rabbette |
| Hjemsted | Dublin,
du Irland |
| Websted | |
| Børsnotering | 17.07.2019 |
| Medarbejdere | 3.500 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
London Stock Exchange | UPR.L |
Frankfurt | 0NR.F |
London | UPR.L |
München | 0NR.MU |
Düsseldorf | 0NR.DU |